智通财经6月6日电，固态电池概念震荡走强，海辰药业封20CM涨停，此前德新科技涨停，厦钨新能、 领湃科技、金龙羽、科恒股份等涨幅靠前。消息面上，据了解，固态电池有望在2027年前启动装车验 证，2030年实现量产化应用。中商产业研究院预测，到2030年，固态电池出货量将超65GWh。 固态电池概念震荡走强 海辰药业20CM涨停 ...

创新药板块局部活跃，海辰药业（300584）涨超10%，联化科技（002250）涨超8%，圣诺生物、迈威 生物、昂利康（002940）等股拉升。 ...

一致。 二、权益分派方案 证券代码：300584 证券简称：海辰药业 公告编号：2025-026 南京海辰药业股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 南京海辰药业股份有限公司（以下简称"本公司"或"公司"）2024 年度 利润分配方案已获 2025 年 5 月 28 日召开的 2024 年度股东大会审议通过，股东 大会决议公告已于同日在中国证监会指定创业板信息披露网站上披露。现将权益 分派事宜公告如下： 一、股东大会审议通过的利润分配方案情况 配现金红利总额为 12,000,000.00 元,不送红股，不以资本公积金转增股本。本 次方案实施完毕后，剩余未分配利润结转入下一年度。 若在分配方案实施前公司总股本发生变化的，公司将按照分配比例不变的原 则对分配总额进行调整。 序号 股东账号 股东名称 在权益分派业务申请期间（申请日：2025 年 5 月 29 日至登记日：2025 年 6 月 6 日），如因自派股东证券账户内股份减少而导致委托中国结算深圳分公司代 派的现金红利不足的，一切法律责任与后果由我公司自行承担。 六、咨询机构 咨询机构： ...

南京海辰药业股份有限公司 2024 年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 南京海辰药业股份有限公司（以下简称"本公司"或"公司"）2024 年度 利润分配方案已获 2025 年 5 月 28 日召开的 2024 年度股东大会审议通过，股东 大会决议公告已于同日在中国证监会指定创业板信息披露网站上披露。现将权益 分派事宜公告如下： 证券代码：300584 证券简称：海辰药业 公告编号：2025-026 售股、股权激励限售股及无限售流通股的个人股息红利税实行差别化税率征收， 本公司暂不扣缴个人所得税，待个人转让股票时，根据其持股期限计算应纳税额 【注】；持有首发后限售股、股权激励限售股及无限售流通股的证券投资基金所 涉红利税，对香港投资者持有基金份额部分按 10%征收，对内地投资者持有基金 份额部分实行差别化税率征收），本年度不以公积金转增股本，不送红股。在利 润分配预案披露日至实施权益分配股权登记日期间，因新增股份上市、股权激励 授予或行权、可转债转股、股份回购等事项导致公司股本发生变动的，公司将按 照分配比例不变的原则对分配总额 ...

江苏世纪同仁律师事务所关于 南京海辰药业股份有限公司2024年度股东大会的 法 律 意 见 书 南京海辰药业股份有限公司： 根据《中华人民共和国公司法》《中华人民共和国证券法》和中国证监会 发布的《上市公司股东会规则》等法律、法规和规范性文件以及《南京海辰药 业股份有限公司章程》（以下简称"《公司章程》"）的规定，本所受公司董 事会的委托，指派本律师出席公司 2024 年度股东大会，并就本次股东大会的召 集、召开程序、出席会议人员资格、召集人资格、表决程序以及表决结果的合 法有效性等事项出具法律意见。 为出具本法律意见书，本律师对本次股东大会所涉及的有关事项进行了审 查，查阅了相关会议文件，并对有关问题进行了必要的核查和验证。 本律师同意将本法律意见书随公司本次股东大会决议一并公告，并依法对 本法律意见书承担相应的责任。 本律师根据相关法律、法规和规范性文件的要求，按照律师行业公认的业 务标准、道德规范和勤勉尽责精神，出具法律意见如下： 一、关于本次股东大会的召集、召开程序和召集人资格 1.本次股东大会由董事会召集。2024 年 4 月 18 日，公司召开了第四届董事 会第二十次会议，决定于 2025 年 5 ...

证券代码：300584 证券简称：海辰药业 公告编号：2025-025 南京海辰药业股份有限公司 2024 年度股东大会决议公告 1、本次股东大会无否决议案的情形。 2、本次股东大会无涉及变更以往股东大会已通过决议的情形。 一、会议召开和出席情况 1、公司于2025年4月21日在巨潮资讯网（http://www.cninfo.com.cn）披 露了《关于召开2024年度股东大会通知公告》。 2、会议召开的方式：以现场投票和网络投票相结合的方式召开。 3、会议召开的日期、时间 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： (1) 现场会议召开时间：2025年5月28日（星期三）下午14:00； (2) 网络投票时间：2025年5月28日； 其中，通过深圳证券交易所交易系统进行网络投票的时间为：2025年5月28 日（星期三）9:15-9:25、9:30-11:30、13:00-15:00；通过深圳证券交易所互 联网投票系统进行投票的具体时间为：2025年5月28日（星期三）9:15-15:00。 4、现场会议地点：公司会议中心三楼会议室，南京经济技 ...

Group 1 - The innovative drug concept stocks are experiencing a downturn, with several companies seeing declines of over 5% [1] - Notable companies affected include Sanofi, Haisun Pharmaceutical, Huisheng Biological, Rejing Biological, Haichuang Pharmaceutical, and Ruizhi Pharmaceutical [1] - Other companies such as Saiseng Pharmaceutical and Hasan Union are also following the downward trend [1]

Market Overview - The three major A-share indices collectively adjusted in the morning session, with the Shanghai Composite Index down 0.30%, the Shenzhen Component Index down 0.71%, and the ChiNext Index down 1.28% [1] - The total market turnover for the half-day was 661 billion, a decrease of 1 billion compared to the previous day, with 2,600 stocks in the market showing losses [1] Sector Performance - The controllable nuclear fusion, gaming, and beverage manufacturing sectors led the gains, while the innovative drug sector experienced the largest declines [2] - Notable stocks in the controllable nuclear fusion sector included Haohan Huadong (301137), Xue Ren Co., Ltd. (002639), and Rongfa Nuclear Power (002366), all hitting the daily limit [2] - Gaming stocks also performed well, with Youzu Network (002174) reaching the daily limit [2] - Beverage manufacturing stocks rebounded, with Junyao Health (605388) and Kuaijishan (601579) hitting the daily limit [2] - The autonomous driving sector showed strength, with Jinjiang Online (600650), Tongda Electric (603390), and Longzhou Co., Ltd. (002682) all reaching the daily limit [2] - The innovative drug sector saw significant declines, with Haichen Pharmaceutical (300584) dropping over 10%, and Hainan Hai Pharmaceutical (000566) and San Sheng Guojian also experiencing notable losses [2] Hotspot Overview - The nuclear power sector was highlighted as the strongest market focus, with 11 stocks hitting the daily limit and 5 stocks achieving consecutive limit-ups, including Shangwei Co., Ltd. and Zhongchao Holdings (002471) [7] - The military industry sector also saw 11 stocks hitting the daily limit, with 5 stocks achieving consecutive limit-ups [8] - The artificial intelligence sector had 9 stocks hitting the daily limit, with one stock achieving consecutive limit-ups [9] Key Developments - The controllable nuclear fusion sector is gaining attention following U.S. President Trump's recent executive orders aimed at launching the construction of 10 large nuclear power plants by 2030 and quadrupling the nuclear power capacity by 2050 [10] - The IP economy is also gaining traction, with stocks like Youzu Network and others seeing significant interest, particularly following the recent rise in the market value of Pop Mart in Hong Kong [11] - The autonomous driving sector is attracting capital, with recent funding rounds for companies like Jiushi Intelligent and New Stone Technology, indicating strong investor interest in this area [12]

Core Viewpoint - The A-share pharmaceutical sector is experiencing significant fluctuations, with notable declines in several companies' stock prices, indicating a broader market adjustment in this industry [1] Company Summary - Haichen Pharmaceutical has seen its stock price drop by over 10% [1] - Key competitors such as Keyuan Pharmaceutical and Tuoxin Pharmaceutical have also faced declines, with drops exceeding 8% [1] - Other companies in the sector, including Duori Pharmaceutical, Ruizhi Pharmaceutical, and Nuotai Biological, are also experiencing downward trends in their stock prices [1]

Market Overview - On May 23, the A-share market showed strong performance before noon but retreated in the afternoon, with the Shanghai Composite Index down 0.94% to 3348.37 points, the Shenzhen Component Index down 0.85% to 10132.41 points, and the ChiNext Index down 1.18% to 2021.50 points [2] - The total market turnover was 118.26 billion yuan, an increase of 42.9 billion yuan compared to the previous trading day [2] - Leading sectors included pharmaceuticals, automotive supply chains, and controllable nuclear fusion, while previously popular micro-cap stocks continued to adjust [2] Pharmaceutical Sector - The pharmaceutical sector experienced a strong surge, with leading innovative drug company Heng Rui Pharmaceutical listing on the Hong Kong Stock Exchange and seeing its stock price rise over 25%, boosting the entire innovative drug industry chain [3] - A-share pharmaceutical stocks rose against the trend, with companies like Hai Chen Pharmaceutical and Zhong Sheng Pharmaceutical hitting the daily limit, while Hua Sen Pharmaceutical and Cheng Da Pharmaceutical also saw gains [3] - Multiple innovative drug companies announced they would showcase their research results at the 2025 American Society of Clinical Oncology (ASCO) annual meeting from May 30 to June 3 [3] - The market's expectations for domestic innovative drugs going global were heightened following the news of a dual-antibody new drug licensing collaboration between Sanofi and Pfizer [3] - According to NextPharma, Chinese pharmaceutical companies completed 41 overseas licensing transactions in Q1 2025, totaling 36.9 billion USD, nearing the total for the entire year of 2023 [3] - From 2015 to 2024, China ranked first globally in the cumulative number of original innovative drugs developed [4] - Zhonghang Securities noted that the innovative drug industry is undergoing profound changes, with companies enhancing their core advantages and transitioning from followers to significant players in international competition [3] Micro-Cap Stocks - Micro-cap stocks initially performed well but began to adjust from mid-week, with high-profile stocks like Nanjing Port and Langsha experiencing significant fluctuations [5] - Wangzi New Materials gained attention from active market funds, achieving a limit-up on May 23 and recording five consecutive trading days of gains, effectively doubling in value [5] - According to Founder Securities, the dominance of micro-cap stocks has been a notable feature of the A-share market this year, with strong mean reversion properties observed in small-cap styles [5] - The outlook for the market suggests that the trend favoring micro-cap stocks may continue, supported by factors such as a stable capital market, ongoing economic transformation, and sustained liquidity [5]